Abbott Laboratories Non-GAAP EPS of $1.30 in-line, revenue of $11.37B misses by $20M

Abbott Laboratories press release (NYSE:ABT): Q3 Non-GAAP EPS of $1.30 in-line.
Revenue of $11.37B (+6.9% Y/Y) misses by $20M.
Third-quarter sales increased 6.9 percent on a reported basis, 5.5 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales
Abbott reaffirms previously provided full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales, or 6.0% to 7.0%, when including COVID-19 testing-related sales. Abbott also reaffirms the midpoint of the previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18 vs $5.14 consensus, which reflects double-digit growth at the midpoint.
Shares -5.7% PM.